Hemogenyx Pharmaceuticals (LON:HEMO) Stock Breaks Above 50-Day Moving Average – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of GBX 583.34 and traded as high as GBX 650. Hemogenyx Pharmaceuticals shares last traded at GBX 650, with a volume of 14,431 shares changing hands.

Hemogenyx Pharmaceuticals Stock Performance

The stock has a market capitalization of £43.04 million, a PE ratio of -4.77 and a beta of 1.49. The company has a debt-to-equity ratio of 42.86, a current ratio of 4.04 and a quick ratio of 6.72. The business’s fifty day moving average price is GBX 586.50 and its 200-day moving average price is GBX 752.85.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its quarterly earnings data on Monday, September 28th. The company reported GBX (101.70) EPS for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.